Additive and synergistic pharmacologic inhibition of equine fibrinoligase (factor XIIIa*-like) biochemical activity.

This research study evaluated various pharmaceutical compounds’ ability to inhibit the biochemical activity of a specific enzyme called fibrinoligase, or factor XIIIa*, in horse blood plasma. The aim was to discover if these compounds can essentially ‘block’ the function of this enzyme, thus preventing coagulation and shedding light on new potential treatments for blood-related ailments.

Selection Criteria for Pharmaceuticals

• The pharmaceuticals tested in this study were carefully selected based on their potential to affect the activity of coagulation factor XIIIa*, which drives a key reaction in the body’s coagulation process, namely, transglutamination. This reaction involves the covalent bonding of fibrin monomers — a crucial step in clots formation.
• The selection was also influenced by the molecular structure and chemical composition of amino acid residues possibly involved in the covalent fibrin monomer polymerization process mediated by this enzyme.

Pharmaceuticals Tested and Methodology

• Varying compounds were tested individually and in combination to ascertain whether there might be an additive or synergistic effect in inhibiting factor XIIIa*.
• Pharmaceuticals with a carbonylamide, such as cefuroxime, Girard’s reagent-P, and prolinamide, were tested along with compounds with a terminal amine, like D-arginine and L-lysine, a method designed to simulate the natural biochemical process that occurs during transglutamination.
• Halogen-dinitro and ethylene compounds, known for their ability to inhibit enzyme systems that rely on an intact sulfhydryl group at their biochemically active site (for example, the cystine amino acid residue), were also evaluated.

Research Outcomes

• The tested group of pharmaceutical compounds, unfortunately, did not succeed in inhibiting the biochemical activity overseen by coagulation factor XIIIa* in horse plasma.
• These results suggest that these compounds may not be suitable as potential treatments aimed at controlling or altering the process of coagulation in horse blood.